BBA
TGTX icon

Baader Bank Aktiengesellschaft’s TG Therapeutics TGTX Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,618
Closed -$492K – 511
2025
Q1 		$492K Buy
+12,618
New +$425K 0.04% 235
2024
Q4 		– Sell
-25,500
Closed -$596K – 496
2024
Q3 		$596K Buy
+25,500
New +$557K 0.03% 226

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baader Bank Aktiengesellschaft's TGTX Position: Q2 2025 in Review

Baader Bank Aktiengesellschaft sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 12,618 shares — an estimated $492K sold.

Baader Bank Aktiengesellschaft first reported a position in TGTX in Q3 2024 and held it in 2 quarters. The position peaked at $596K in Q3 2024. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Baader Bank Aktiengesellschaft reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 12,618 TG Therapeutics shares in Q2 2025, an estimated $492K.
  • Baader Bank Aktiengesellschaft first reported a position in TG Therapeutics in Q3 2024 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's TG Therapeutics position peaked at $596K in Q3 2024.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2025, filed 10 Jul 2025.